November 1, 2007Journal of Hospital Medicine
Discontinuation of antiplatelet therapy prior to low‐risk noncardiac surgery in patients with drug‐eluting stents: A retrospective cohort study
Key result
In patients with drug-eluting stents undergoing low-risk noncardiac surgery, the 30-day rate of stent thrombosis was 0% (95% CI 0%-3.3%) even after discontinuation of antiplatelet agents.
Population
114 patients who had undergone drug-eluting stent placement and subsequently were evaluated for low-risk…
Design
Cohort
Follow-up
30-day
Authors
Discussion
Loading...
Member takes
Implication
May inform antiplatelet management before low-risk surgery after DES; leaves open need for larger prospective studies.
Study Design
Type
Cohort (n=114)
Multicenter
No
Structured PICO
P
Population
114 patients with drug-eluting stents who underwent noncardiac surgery a median of 236 days after stent placement, evaluated for 30-day postoperative outcomes.
E
Exposure
Discontinuation of all antiplatelet agents prior to surgery (median 10 days before surgery)
O
Outcome
30-day rate of postoperative myocardial infarction (MI), DES thrombosis, major bleeding, and all-cause mortalityhard clinical
Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents appears to carry a low risk of stent thrombosis, particularly when surgery occurs at least 180 days post-stenting.
Cite This Study
Brotman et al. (2007) conducted a cohort in Drug-eluting stents prior to low-risk noncardiac surgery (n=114). Discontinuation of antiplatelet therapy was evaluated on 30-day rate of postoperative myocardial infarction (MI), DES thrombosis, major bleeding, and all-cause mortality. In patients with drug-eluting stents undergoing low-risk noncardiac surgery, the 30-day rate of stent thrombosis was 0% (95% CI 0%-3.3%) even after discontinuation of antiplatelet agents.